Compare CAC & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAC | DNA |
|---|---|---|
| Founded | 1875 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.5M | 562.3M |
| IPO Year | 1997 | N/A |
| Metric | CAC | DNA |
|---|---|---|
| Price | $43.33 | $8.21 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 3 | 1 |
| Target Price | ★ $47.33 | $9.00 |
| AVG Volume (30 Days) | 78.6K | ★ 1.0M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | ★ 9.13 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $215,172,000.00 | $180,606,000.00 |
| Revenue This Year | $44.50 | N/A |
| Revenue Next Year | $7.82 | $7.28 |
| P/E Ratio | $12.42 | ★ N/A |
| Revenue Growth | ★ 27.50 | N/A |
| 52 Week Low | $34.53 | $5.00 |
| 52 Week High | $46.80 | $17.58 |
| Indicator | CAC | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 50.18 | 39.61 |
| Support Level | $43.60 | $8.09 |
| Resistance Level | $46.80 | $9.12 |
| Average True Range (ATR) | 0.86 | 0.53 |
| MACD | -0.39 | 0.01 |
| Stochastic Oscillator | 3.15 | 6.00 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.